a UGC Centre of Advanced Studies , University Institute of Pharmaceutical Sciences, Panjab University , Chandigarh , India.
b UGC-Centre of Excellence in Applications of Nanomaterials , Nanoparticles and Nanocomposites, Panjab University , Chandigarh , India.
Expert Opin Drug Deliv. 2019 Feb;16(2):101-112. doi: 10.1080/17425247.2019.1560418. Epub 2018 Dec 24.
Actinic keratosis is one of the most common disorder characterized by erythematic and generally attached scaly lesions which are present either alone or in clusters. World Health Organization defines actinic keratosis as a common intraepidermal neoplasm of sun-damaged skin, characterized by variable atypia of keratinocytes.
At the beginning of the 20th century, a new immunomodulator molecule, imiquimod, appears in the market for the treatment of actinic keratosis but suffers from the pitfalls of the conventional approach of dosage form preparation including high dose, poor stability and more side effects. The present article attempts to compile the scatter information related to actinic keratosis and imiquimod at one place. The special emphasis will be made on the information available in various research articles and patents with respect to the efforts made for overcoming shortcomings associated with imiquimod by novel drug delivery or other approaches.
The conventional drug delivery systems are unsuccessful to improve the actinic keratosis. The patient acceptance and compliance with these treatments are generally poor due to associated side effects, poor cosmetic outcomes and high costs. Therefore, several available and reported novel therapeutic approaches are being developed in order to provide better action.
光化性角化病是最常见的疾病之一，其特征为红斑和通常附着的鳞屑性病变，这些病变单独存在或成簇存在。世界卫生组织将光化性角化病定义为一种常见的表皮内肿瘤，发生于日光损伤的皮肤，其特征为角质形成细胞的异型性不定。
在 20 世纪初，一种新的免疫调节剂分子，咪喹莫特，出现在市场上用于治疗光化性角化病，但它也存在传统剂型制备方法的缺陷，包括高剂量、稳定性差和更多的副作用。本文试图将与光化性角化病和咪喹莫特相关的分散信息汇集在一起。特别强调的是，在各种研究文章和专利中，有关通过新型药物传递或其他方法克服咪喹莫特相关缺点所做的努力的信息。
传统的药物传递系统不能改善光化性角化病。由于相关的副作用、美容效果不佳和成本高，患者对这些治疗的接受度和依从性通常较差。因此，正在开发几种现有的和报道的新型治疗方法，以提供更好的效果。
